Latest revenue
$60.1M
as of 2026-03-31
Latest net income
$-55.6M
as of 2026-03-31
Net margin
-92.6%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $6.02B
- Enterprise value
- $6.02B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $122.20
- 52-wk low
- $58.71
- Beta
- —
- Shares out
- 68.5M
5-year trend
What this company does
Item 1. Business Overview We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. While obesity affects hundreds of millions of people worldwide, we are developing therapies for a subset of individuals who have hyperphagia, a pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, decreased energy expenditure…
AI summary unavailable — showing raw filing excerpt
Generated from RYTM's filing dated 2026-02-26
Key risks
PART II - OTHER INFORMATION Item 1A. Risk Factors Our operations and financial results are subject to various risks and uncertainties, including those described below, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. Additional risks and uncertainties that we currently do not know about or that we currently believe to be immaterial may also impair our business. You should carefully consider the risks described below and the other information in this Annual Report on Form 10-K for the period ended December 31, 2025 (the “Annual Report”), including our audited consolidated financial statements and the…
AI summary unavailable — showing raw filing excerpt
Generated from RYTM's filing dated 2026-02-26
Profitability
Operating margin
-101.2%
50.4%Net margin
-103.6%
48.3%Return on equity
-141.3%
7.9%Return on assets
-40.9%
38.4%Leverage
Debt / equity
2.45×
87.1%Long-term debt / equity
0.73×
13.7%Debt / assets
71.0%
25.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $60.1M | +83.8% | $-55.6M | -12.4% | -92.6% |
Q4 2025 2025-12-31 | $57.3M | +36.9% | $-47.5M | -9.6% | -83.0% |
Q3 2025 2025-09-30 | $51.3M | +54.3% | $-52.9M | -21.2% | -103.1% |
Q2 2025 2025-06-30 | $48.5M | +66.8% | $-46.6M | -44.5% | -96.1% |
Q1 2025 2025-03-31 | $32.7M | +25.9% | $-49.5M | +65.0% | -151.4% |
Q4 2024 2024-12-31 | $41.8M | — | $-43.3M | — | -103.6% |
Q3 2024 2024-09-30 | $33.3M | +47.8% | $-43.6M | +1.2% | -131.2% |
Q2 2024 2024-06-30 | $29.1M | +51.3% | $-32.3M | +30.9% | -110.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on RYTM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$29.5M
Net activity
−$29.5M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns RYTM
Institutional value
$2.51B
Total shares held
29.1M
Distinct holders
148
-129 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.2M | $542.4M | -60.2K (-1.0%) | Trimmed |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 3.4M | $297.2M | -61.2K (-1.8%) | Trimmed |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.0M | $264.5M | — | New |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $258.1M | — | New |
| 5 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1.9M | $167.8M | +662.0K (+52.2%) | Added |
| 6 | JPMORGAN CHASE & CO | 1.6M | $120.0M | +129.7K (+9.1%) | Added |
| 7 | FEDERATED HERMES, INC. | 1.3M | $111.9M | -337.5K (-20.8%) | Trimmed |
| 8 | Capital Research Global Investors | 1.1M | $97.0M | +130.4K (+13.2%) | Added |
| 9 | Pictet Asset Management Holding SA | 667.0K | $57.3M | +52.4K (+8.5%) | Added |
| 10 | FRANKLIN RESOURCES INC | 626.8K | $54.5M | -68.9K (-9.9%) | Trimmed |
| 11 | Clearbridge Investments, LLC | 609.4K | $53.0M | +103.3K (+20.4%) | Added |
| 12 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 541.5K | $47.1M | -7.6K (-1.4%) | Trimmed |
| 13 | Candriam S.C.A. | 464.3K | $40.4M | -111.5K (-19.4%) | Trimmed |
| 14 | VANGUARD FIDUCIARY TRUST CO | 421.9K | $36.7M | — | New |
| 15 | Artisan Partners Limited Partnership | 390.7K | $34.0M | +127.1K (+48.2%) | Added |
| 16 | Invesco Ltd. | 364.3K | $31.7M | +73.2K (+25.1%) | Added |
| 17 | Bank of New York Mellon Corp | 293.3K | $25.5M | -7.8K (-2.6%) | Trimmed |
| 18 | BNP PARIBAS FINANCIAL MARKETS | 247.9K | $21.6M | +83.3K (+50.6%) | Added |
| 19 | Voya Investment Management LLC | 233.8K | $20.3M | -16.1K (-6.4%) | Trimmed |
| 20 | UBS Group AG | 231.7K | $20.1M | -195.6K (-45.8%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once RYTM's latest filing finishes processing.